@JCFINT profile picture
JCF Intersections @JCFINT

The OA journal exploring heart failure and its intersection with different fields of medicine. Find out more: onlinejcfi.org

Joined November 2024
  • Tweets 89
  • Following 182
  • Followers 276
62 Photos and videos
Anthracycline cardiotoxicity remains a major challenge in cardio-oncology. This meta-analysis suggests SGLT2i may reduce mortality, HF events, & arrhythmias in anthracycline-treated patients, with reassuring safety signals. A promising prevention strategy? 🫀 Link below 👇
1
4
6
537
🔗 bit.ly/4o2aGOs

Cardiovascular Impacts of SGLT2 Inhibitors on the Mitigation of Anthracycline-Induced Cardiomyopa...

Cardiovascular disease (CVD) and cancer remain the leading causes of global mortality and morbidity, collectively accounting for two-thirds of all mortality.1 Due to reductions in smoking, earlier...

onlinejcfi.org
57
JCF Intersections@JCFINT
May 26
New month. New conversations in heart failure. The May issue of JCF-Intersections is out now featuring fresh insights, expert perspectives, and meaningful discussion from across the field. onlinejcfi.org/current
8
10
4,833
Should cardiogenic shock teams become the standard of care? It's up for debate!🫀 One viewpoint argues yes: multidisciplinary shock teams can streamline diagnosis, coordinate care & improve outcomes across institutions. Observational data support their impact. 🧵👇
1
7
15
3,218
more replies
Another view urges caution: CS care is time-sensitive, & assembling teams could delay treatment. Clear, evidence-based protocols may be just as important as the team itself. The future likely lies in combining structured pathways with multidisciplinary care.⚖️ 🧵👇
1
2
2
225
🔗 bit.ly/3NzhViZ

Cardiogenic Shock Teams: Proceed With Caution

Cardiogenic shock (CS) carries a high morbidity and mortality and is rapidly progressive, with greater Society for Cardiovascular Angiography and Interventions (SCAI) shock stages being associated...

onlinejcfi.org
1
3
186
JCF Intersections@JCFINT
Apr 28
tMCS (e.g., VA-ECMO) can save lives—but what if there’s no path forward? A new perspective examines the ethical challenge of the “bridge to nowhere” and explores concepts like dynamic consent, moral distress, distributive justice, and so much more⚖️🫀 🔗 bit.ly/41oRsrt
8
12
1,342
JCF Intersections@JCFINT
Apr 15
LVAD offers a stable platform to help patients overcome barriers to heart transplant. In one cohort, ~70% had modifiable barriers and 60% of these resolved at least one after LVAD, highlighting the role of multidisciplinary care.🫀📊 🔗 bit.ly/4uPEHUy
1
9
18
1,711
JCF Intersections@JCFINT
Apr 9
Cardiogenic shock → low CO & end-organ hypoperfusion. LV failure is common, but don’t miss other causes: valvular disease, mechanical MI complications, or RV failure. A systematic approach bedside echo can rapidly guide diagnosis and escalation.🫀 🔗 bit.ly/4uPBSTs
9
34
9,566
JCF Intersections@JCFINT
Mar 19
JCF Intersections is out now! Where research meets perspective, and new ideas take shape across disciplines. Explore the latest 👉 onlinejcfi.org/current #HeartFailure #Cardiology
6
11
630
A HFrEF polypill💊 could ⬆️ GDMT uptake, but prescriber prefs are unknown. Using a 5-stage mixed-methods process, researchers built a discrete choice experiment to test cardiologists’ prefs—work that will directly inform future HFrEF polypill clinical trials. Read more 👇
2
4
16
1,218
🔗 bit.ly/3ZmjsLp
1
1
225
JCF Intersections@JCFINT
Feb 3
New science 🚨! In an analysis of centrifugal-flow LVAD trials, digoxin💊 users showed greater improvement in 6MWT 🚶 vs no digoxin (especially in older pts) with similar QOL & AE rates. Digoxin was also linked to better 4-yr survival in NICM pts. 🔗 bit.ly/4r5phsy
1
3
14
604
JCF Intersections@JCFINT
Jan 27
📣 Last chance to register for JCF-I Office Hours! Join Editor in Chief Dr. Katz and Deputy Editor Dr. Reza to answer your questions on: ✅ JCF-I's upcoming publications ✅ What they are looking for in submissions ✅ Updates on the year ahead bit.ly/3NmOKz4
2
11
571
JCF Intersections@JCFINT
Jan 22
The January issue of JCF-I is now available 👉 bringing forward new evidence, perspectives, and conversations in heart failure various intersections. Read the full issue 📖onlinejcfi.org/current
1
4
222
JCF Intersections@JCFINT
Jan 21
Time is running out! Register for JCF-I Office Hours⌛ Join Editor in Chief Dr. Katz and Deputy Editor Dr. Reza to answer your questions on: ✅ JCF-I's upcoming publications ✅ What they are looking for in submissions ✅ Updates on the year ahead bit.ly/3NmOKz4
2
8
503
JCF Intersections@JCFINT
Jan 15
🚨 JCF-I Office Hours Join Editor in Chief Dr. Katz and Deputy Editor Dr. Reza to answer your questions on: ✅ JCF-I's upcoming publications ✅ What they are looking for in submissions ✅ Updates on the year ahead Register: bit.ly/3NmOKz4
5
20
1,985
📢 New study in JCF-I on the safety and effectiveness of a low-carbohydrate ketogenic diet LCKD for weight loss in patients with overweight/obesity and HF. This is one of the largest real-world looks at LCKD use in HF. 🫀🍽️ See below ⬇️ bit.ly/3Ka9yZz
1
2
10
398
🍽️ Key Highlights -125 overweight/obese HF patients Rx LCKD were followed for avg 2 years -Median weight loss: 11.2 kg (p<0.01) -No ⬇️ in EF -Significant ⬇️ in HF 🏥 in HFpEF, numerically lower in HFrEF -LCKD was safe, with improvements in several metabolic markers
1
1
3
178
Overall, meaningful weight loss and potential cardiac benefits. Read more 👉 bit.ly/3Ka9yZz
1
2
164
Load more